Aggressive Treatment Fails to Improve Outcomes in Early-Onset CRC

Data presented at the ESMO Gastrointestinal Cancers 2026 Annual Congress suggest that early-onset colorectal cancer (EOCRC) is not merely a younger version of late-onset disease but a distinct clinical and biological entity.

Despite receiving significantly more aggressive systemic therapies, younger patients diagnosed with colorectal cancer (CRC) continue to experience poorer survival outcomes than their older counterparts.

EOCRC, defined as a diagnosis before age 50, has become a burgeoning public health challenge worldwide, largely driven by an increase in rectal and distal adenocarcinomas. Current oncology guidelines typically recommend that treatment for EOCRC should mirror strategies used for average-onset colorectal cancer (AOCRC). However, the findings from a large retrospective study conducted in Montevideo, Uruguay, challenge this "one-size-fits-all" approach.

The context

The study, led by Santiago Fontes and colleagues, analyzed 1,538 clinical records of patients diagnosed between 2010 and 2025. Uruguay provides a unique backdrop for this research; as a highly urbanized country with a "very high" Human Development Index, it reports the highest incidence of CRC in Latin America and ranks among the highest globally.

Of the total patient population, 16% were diagnosed with EOCRC, with a mean age at diagnosis of 44 years. Within this younger cohort, 56% were female and 41% were classified as overweight. Notably, 20% of these patients had a documented family history of CRC, while 19% presented with polyps at the time of diagnosis.

A disparity in treatment intensity

The research highlighted a significant trend toward more intensive treatment in younger patients. In the first-line setting for metastatic disease, EOCRC patients were more likely to receive triplet chemotherapy regimens combined with targeted agents. For instance, 11% of EOCRC patients received a triplet plus anti-VEGF therapy, compared to only 3% of the AOCRC group.

The use of anti-EGFR therapies also showed a marked age-based disparity: 23% of EOCRC patients received anti-EGFR agents in the first line, compared to just 9% of older patients.

The survival paradox

Despite this aggressive therapeutic approach, the survival data favored the older population. Kaplan-Meier survival curves presented at the congress demonstrated that EOCRC patients had poorer overall outcomes than the 60–75-year-old AOCRC group.

The study authors noted that younger patients often face a "trend toward overtreatment" that does not translate into a survival benefit. This discrepancy suggests that the underlying biology of EOCRC may be more resistant to standard aggressive protocols or that the disease itself possesses distinct molecular drivers.

Biological and clinical distinctions

Tumor characteristics in the EOCRC cohort further supported the "distinct entity" hypothesis. Grade II adenocarcinomas were common, and 14% of cases exhibited mucinous features. In terms of tumor location, EOCRC was predominantly found in the rectum and rectosigmoid junction (48%), followed by the left colon (29%) and right colon (23%).

The researchers also observed a potential enrichment of RAS mutations, particularly in a subanalysis of patients aged 35 and younger (ultra-early onset CRC). This molecular profile, combined with the anatomical distribution and poor response to intensified therapy, underscores the need for EOCRC-specific clinical trials rather than extrapolating data from older populations.

Implications for oncology nursing

For oncology nurses, these findings emphasize the importance of nuanced patient management. Younger patients are not only dealing with a more aggressive disease course but also the cumulative toxicities associated with triplet chemotherapy and intensive targeted agent use.Nurses play a critical role in:

• Family history screening: Given that 20% of the EOCRC cohort had a family history of CRC, diligent pedigree assessment and referral for genetic counseling remain vital.
• Symptom management: Managing the side effects of intensive regimens like mFOLFIRINOX in a population that is frequently "overtreated" requires proactive intervention.
• Psychosocial support: Younger patients often face unique challenges regarding career, fertility, and long-term survivorship, especially when survival outcomes are less favorable.

As the researchers concluded, the current practice of aggressive treatment without clear survival benefits in younger patients warrants "careful consideration in clinical practice."

Future research must focus on identifying the specific biological drivers of EOCRC to move beyond overtreatment and toward precision care.

Reference

Fontes S, Marín A, Wagner G, et al. Systemic treatment patterns and outcomes—a distinct disease? Poster presented at: ESMO Gastrointestinal Cancers Annual Congress; July 1-4, 2026; Munich, Germany.